Cover Image
市場調查報告書

出生前診斷的全球市場

Prenatal Diagnostics

出版商 Global Industry Analysts, Inc. 商品編碼 248920
出版日期 內容資訊 英文 197 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
出生前診斷的全球市場 Prenatal Diagnostics
出版日期: 2016年06月01日 內容資訊: 英文 197 Pages
簡介

本報告,提出出生前診斷的全球市場,進行美國、加拿大、日本、歐洲、亞太地區、拉丁美洲及其他地區等各地區的個別分析,提供各地區過去的實績及將來的預測,並彙整主要企業及利基企業共38家的檔案資料等,由下列摘要形式闡述。

第1章 簡介、調查方法、產品定義

  • 調查的信賴性與報告的限制
  • 免責聲明
  • 資料的解釋與報告的等級
    • 定量技法及分析法
  • 產品定義與調查範圍

第2章 報告摘要

  • 整體概要
    • 預估將擴大的出生前檢查市場
    • 出生前檢查:改變懷孕護理領域
    • 出生前檢查:基本概要
    • 所提供的出生前篩檢及診斷檢查的適應別一覽表
    • 染色體異常為出生前檢查領域的主導症狀
    • 基因檢查在基因症狀診斷上扮演重要角色
    • 出生前基因檢查的原理
    • 出生前基因檢查的抬頭
    • 非侵入性出生前檢查:漫漫長路
  • 產業概要
    • 出生前治療的必要性:出生前檢查的基礎
    • 出生前檢查於因應早產時的角色
    • 諮詢服務:出生前檢查前後不可或缺的手續
    • 實現勢力的具備促進出生前檢查市場
    • 低敏感度與低特異性的既有檢查:新檢查的案例準備中
    • 高敏感度的血清檢查的導入者可能不多
    • 傳統型出生前診斷手法:有風險的方法
    • 既有侵入性技法的其他否定要素
    • NIPD(非侵入性出生前診斷)排除傳統型診斷順序的風險與不確定性
    • 對於NIPD技法的反對意見:導入上的巨大阻礙
    • 倫理問題使出生前檢查的利益與普及動彈不得
    • NIPD檢查的利益超過阻礙
    • 影響NIPD檢查普及的主要因素
    • 與篩選檢查的置換:NIPD所造成可想像的變化
    • 可能的NIPD多樣使用
    • 超音波:與血液型篩選檢查的必要結合
  • 用途概要
    • 染色體異常:巨大經濟負擔
    • 基因異常的事件別、基因發現別、及病患數一覽表
    • 出生前唐氏症檢查的巨大機會是存在的
    • 為T21的篩檢及確認的主要篩選檢查一覽表
    • 非侵入性出生前診斷可能存在著更大的有用性
    • 唐氏症篩檢/診斷技法
    • Sequenom T21檢查的機會
    • 超越唐氏症:檢查追加的對象非常重要
    • Trisomy 18(三染色體18症)或艾德華氏症:概要
    • Trisomy 13(三染色體13症)或巴陶氏症:概要
    • 囊狀纖維化的篩檢及診斷
    • 囊狀纖維化篩檢市場:非常分裂
  • 技術概要
    • DNA:相較於所有細胞,最適合NIPD分析的標的
    • 出生前檢查的未滿足需求:促進新技術及檢查的重要要素
    • 出生前檢查的定序:潛在的高成長市場
    • NIPI檢查的現在分析手法概要
    • 用於非侵入性出生前診斷的競爭技術比較
    • 使用於侵入性順序由來樣品分析的主要技術
    • 染色體分析
    • 螢光原位雜交(FISH法)
    • 數位PCR:踏入胎兒異數性檢測的領域
    • 大量平行散彈槍定序:可縮短至檢查結果的時間
    • 支援出生前診斷領域的BioCep新技術
    • 出生前診斷上將增加的微陣列型檢查
    • NIPD的所有核酸定序技術:新進展
    • 胎兒DNA造成出生前診斷領域的變革
    • Sequenom由於CCFF核酸檢查的權利取得而大幅躍進
    • 超音波型篩檢的新式次標的在準備中
  • 競爭環境
  • 產品概要
    • 出生前檢查
    • 建議出生前診斷檢查時的考量要素
    • 出生前檢查的種類
    • 出生前篩選檢查
    • 出生前診斷檢查
  • 產品的創新/發表
  • 業界的近期動向
  • 主要國際企業
    • Angle Plc(英國)
    • Hologic, Inc.(美國)
    • PerkinElmer, Inc.(美國)
    • Ravgen, Inc.(美國)
    • Sequenom, Inc.(美國)
    • Sequenom Center for Molecular Medicine, LLC(美國)
    • TrovaGene, Inc.(美國)
  • 全球市場展望

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 其他歐洲
  • 亞太地區
  • 其他地區

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-7675

This report analyzes the worldwide markets for Prenatal Diagnostics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 43 companies including many key and niche players such as -

ANGLE Plc
Ariosa Diagnostics, Inc.
BGI Diagnosis Co., Ltd.
Berry Genomics Co., Ltd.
Hologic, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • Prenatal Testing
      • Prenatal Screening Tests
      • Prenatal Diagnostic Tests
        • Non-Invasive Prenatal Diagnostic Tests

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Prenatal Testing - A Rudimentary Overview
  • List of Available Prenatal Screening and Diagnostic Tests by Indication
  • Prenatal Testing Market to Rise
  • The Rationale for Prenatal Genetic Testing
  • Chromosomal Abnormalities Lead the Prenatal Testing Space
  • Chromosomal Abnormalities - A Substantial Economic Burden
    • List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
  • Counseling - An Imperative Measure Before and After Prenatal Testing
  • Role of Prenatal Testing in Managing Preterm Births
  • Conventional Invasive Prenatal Diagnostic Techniques - A Risky Affair
  • Lower Sensitivity and Specificity of Existing Tests - A Case for New Tests on the Anvil
    • Table 1: List of Available Prenatal Screening/ Diagnostic Tests by Accuracy
  • High Sensitivity Serum Tests May Not Have Many Takers
  • Free Fetal DNA Discovery Revolutionizes Market with Non-Invasive Prenatal Diagnostics (NIPD/NIPT)
  • NIPD Eliminates Risks and Uncertainty of Conventional Diagnostic Procedures
  • Benefits Outweigh Snags in NIPD Tests
  • Major Factors Influencing Penetration of NIPD Tests
    • Table 2: Price Comparison of Existing Tests and Screening Procedures for Down's Syndrome
  • Replacing Screening Tests - A More Conceivable Change through NIPD
  • Diversity in NIPD Usage on the Cards

2. GROWTH DRIVERS & MARKET TRENDS

  • Significant Opportunities in Prenatal Testing for Down's syndrome
  • List of Select Screening Tests Available for T21 Screening and Confirmation
  • Molecular Diagnostics Enhance Prenatal Testing
  • Prenatal Diagnostics: Treading Sensitive Ethical Issues
  • Controversy Related to "Incidental Findings" of Prenatal Tests
  • NGS and MPS - Enabling Shorter Time to Test Results
  • Microarray-Based Testing to See a Boost in Prenatal Diagnosis
  • Whole Genome Sequencing Technology in NIPD - A New Advancement
  • DNA - More Ideal Target for NIPD Analysis than Whole Cells
  • Sequencing in Prenatal Testing - A Potential High Growth Market
  • Ultrasound - An Indispensable Combination with Blood Based Screening Tests
  • New Sub-Targets on the Anvil for Ultrasound-Based Screening
  • Increasing Congenital Disorder Incidence - Key Driver for Prenatal Diagnostics
  • Beyond Down's Syndrome - Need to Test Additional Targets Crucial
  • Trisomy 18 or Edward's Syndrome
  • Trisomy 13 or Patau Syndrome
  • Cystic Fibrosis Screening and Diagnosis
    • Cystic Fibrosis Screening Market - Highly Fragmented
    • ACOG and ACGM Recommendations Boost Demand for Prenatal CF Testing
  • Prenatal Testing Crucial to Detect Risk of Huntington's Disease
  • Prenatal Testing - Effective Way of Alleviating Syphilis Related Deaths and Stillbirths
  • Ballooning Global Female Population Offers Increased Growth Opportunities
    • Table 3: Percentage Share of Female Population in the Age Group (15-54) by Country: 2015
  • Improving Healthcare Expenditure to Drive Demand
    • Table 4: Per-Capita Healthcare Expenditure in Select Regions: 2014 (includes corresponding Graph/Chart)
    • Table 5: Healthcare Spending as a Percentage of GDP by Region: 2014 (includes corresponding Graph/Chart)
  • Market Restraints
  • Opposition to NIPD Technique - A Significant Hurdle to Adoption
  • Unresolved Issues Hamper Widespread Testing for Monogenetic Disease
  • Dearth of Genetic Counselors - A Major Hurdle for Genetic Testing

3. COMPETITIVE ENVIRONMENT

  • Competition Intensifies in the NIPD Market
  • Select Companies Marketing/Developing NIPD Tests
  • Sequenom - A Major Player in the Non-Invasive Test Space
    • Overview of Sequenom NIPD Tests
      • MaterniT21(tm) (Sequenom)
      • SensiGene Fetal (XY)
      • SensiGene Cystic Fibrosis Carrier Screening Test
      • SensiGene Fetal RhD
      • Sequenom's Product Portfolio for Prenatal Diagnostics (As of 2016)
  • Patent Wars in the NIPD Space
  • The Changing Regulatory Paradigm of LDT
  • Verifi(tm) Becomes the First Commercial Test in the Landscape of LDTs
  • TrovaGene's Transrenal Technology

4. PRODUCT OVERVIEW

  • Prenatal Testing
  • Factors Considered for Recommending Prenatal Diagnostic Testing
  • Types of Prenatal Testing
  • Prenatal Screening Tests
    • Evolution of Screening Tests
    • Ultrasound
      • Types of Ultrasound
      • Ultrasound Examination Types and Use in Prenatal Screening of Fetus
    • Triple Screen Test
    • Quad Screen Test
  • Prenatal Diagnostic Tests
    • Chorionic Villus Sampling
      • The Procedure
      • Risks
    • Amniocentesis
      • The Procedure
      • Risks
    • Cordocentesis
      • Procedure
      • Risks
    • Overview of Current Analysis Methods for Invasive Tests
      • Comparison of Competitive Technologies Employed in Invasive Prenatal Diagnosis
  • Major Technologies Used in Analyzing Invasive Procedure-Derived Samples
    • Karyotyping
    • Fluorescence In Situ Hybridization (FISH)
    • Digital PCR - Entering the Realm of Fetal Aneuploidy Detection
      • Lower Fetal DNA Percentage Stifles Progression in Digital PCR Utility Research
      • Non-Invasive Prenatal Diagnostic Tests

5. PRODUCT INNOVATIONS/LAUNCHES

  • Combimatrix to Launch NGS in Pre-implantation Genetic Screening
  • Genetica Launches Panorama NIPT in Switzerland via Natera's Platform
  • Roche and Ariosa Announce Launch of Harmony Test in Australia and UK
  • Source BioScience Launches New NIPT Service
  • Sequenom Laboratories to Launch MaterniT(tm) GENOME Test
  • Ariosa Receives CE Approval for FORTE Software
  • Quest Diagnostics Launches QNatal Advanced NIPT Service
  • Berry Genomics and Illumina Receive Premarket Clearance from CFDA for NextSeq CN500 and NIPT
  • Ariosa Introduces Microarray DNA Quantification for Harmony NIPT
  • LabCorp Launches informaSeq Prenatal Test
  • Eastern Biotech Launches NIPD Test to Detect Trisomy

6. RECENT INDUSTRY ACTIVITY

  • PerkinElmer Divests Prenatal Screening Business to Eurofins Scientific
  • LifeCodexx AG Enters Into Technology Partnerships to Enhance NIPT Availability
  • PerkinElmer Completes Acquisition of Vanadis
  • Applied Spectral Imaging and ScreenCell Enter Into Global Partnership
  • Sequenom Enters into Prenatal Diagnostic Services Agreement with United Healthcare
  • A*STAR's IME and INEX Innovations Collaborate to Develop NIPT
  • Illumina Enters Into Collaboration with Chinese Company Annoroad
  • MedGenome and Natera Enter Into Product License Partnership
  • Roche Acquires NIPT Player Ariosa Diagnostics
  • BGI Europe and NIM Genetics Sign Technology Transfer Agreement
  • Sequenom Acquires NIPT Intellectual Property from Isis Innovation
  • Illumina Signs Agreements to Expand NIPT Reach in Europe
  • BGI Europe and Genomed Enter into Strategic Partnership
  • Illumina Acquires Verinata
  • Quest Diagnostics to Offer Access to Natera's Panorama NIPT

7. FOCUS ON SELECT GLOBAL PLAYERS

  • ANGLE Plc. (UK)
  • Ariosa Diagnostics, Inc. (US)
  • BGI Diagnosis Co., Ltd. (China)
  • Berry Genomics Co., Ltd. (China)
  • Hologic, Inc. (US)
  • Illumina, Inc. (US)
  • Laboratory Corporation of America(r) Holdings (US)
  • Lifecodexx AG (Germany)
  • Natera, Inc. (US)
  • Quest Diagnostics, Inc. (US)
  • Ravgen, Inc. (US)
  • Sequenom, Inc. (US)
  • Sequenom Center for Molecular Medicine, LLC (US)
  • TrovaGene, Inc. (US)

8. GLOBAL MARKET PERSPECTIVE

    • Table 6: World Recent Past, Current & Future Analysis for Prenatal Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 7: World Historic Review for Prenatal Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 8: World 14-Year Perspective for Prenatal Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Current & Future Analysis
    • Leading NIPT Tests
    • Popularity of Screening and ACOG Guidelines Sink Invasive Prenatal Diagnosis Numbers
    • Product Launches
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 9: The US Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 10: The US Historic Review for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Funding Uncertainty
  • B. Market Analytics
    • Table 11: Canadian Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 12: Canadian Historic Review for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN

  • Market Analysis
    • Table 13: Japanese Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 14: Japanese Historic Review for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 15: European Recent Past, Current & Future Analysis for Prenatal Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 16: European Historic Review for Prenatal Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 17: European 14-Year Perspective for Prenatal Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4a. FRANCE

  • Market Analysis
    • Table 18: French Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 19: French Historic Review for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Strategic Corporate Development
    • Lifecodexx AG - A Key German-based Player
  • B. Market Analytics
    • Table 20: German Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 21: German Historic Review for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 22: Italian Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 23: Italian Historic Review for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Current & Future Analysis
    • Increasing Need for Less Risky Prenatal Diagnostic Methods in the UK
    • Product Launch
    • Angle plc - A Key Regional Player
  • B. Market Analytics
    • Table 24: The UK Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 25: The UK Historic Review for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 26: Spanish Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 27: Spanish Historic Review for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
    • Table 28: Russian Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 29: Russian Historic Review for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • A. Market Analysis
    • Product Launch
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 30: Rest of Europe Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 31: Rest of Europe Historic Review for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • China: NGS Assays Widely Used in Domestic NIPT Market
    • Australia: Need for Standardized Approach
    • Product Launches
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 32: Asia-Pacific Recent Past, Current & Future Analysis for Prenatal Diagnostics by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 33: Asia-Pacific Historic Review for Prenatal Diagnostics by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 34: Asia-Pacific14-Year Perspective for Prenatal Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5a. CHINA

  • Market Analysis
    • Table 35: Chinese Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 36: Chinese Historic Review for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5b. INDIA

  • Market Analysis
    • Table 37: Indian Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 38: Indian Historic Review for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5c. REST OF ASIA-PACIFIC

  • Market Analysis
    • Table 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 40: Rest of Asia-Pacific Historic Review for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • Market Analysis
    • Table 41: Latin American Recent Past, Current & Future Analysis for Prenatal Diagnostics by Geographic Region - Brazil, and Rest of Latin American Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 42: Latin American Historic Review for Prenatal Diagnostics by Geographic Region - Brazil, and Rest of Latin American Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 43: Latin American 14-Year Perspective for Prenatal Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for Brazil, and Rest of Latin American Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

6a. BRAZIL

  • Market Analysis
    • Table 44: Brazilian Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 45: Brazilian Historic Review for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6b. REST OF LATIN AMERICA

  • Market Analysis
    • Table 46: Rest of Latin American Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 47: Rest of Latin American Historic Review for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • A. Market Analysis
    • Product Launch
  • B. Market Analytics
    • Table 48: Rest of World Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 49: Rest of World Historic Review for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top